Jun 17, 2024 4:45pm EDT Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
Jun 10, 2024 8:30am EDT Veru to Present at the American Diabetes Association's 84th Scientific Sessions
May 15, 2024 8:30am EDT Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
May 14, 2024 8:30am EDT Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
May 08, 2024 6:30am EDT Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
Apr 30, 2024 8:30am EDT Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
